99 related articles for article (PubMed ID: 30882001)
1. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice.
Gergely PA; Murnyák B; Bencze J; Kurucz A; Varjas T; Gombos K; Hortobágyi T
Biomed Res Int; 2019; 2019():8670398. PubMed ID: 30882001
[TBL] [Abstract][Full Text] [Related]
2. Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[alpha]anthracene-induced onco/suppressor gene action in vivo. I: A 24-hour experiment.
Perjési P; Bayer Z; Ember I
Anticancer Res; 2000; 20(1A):475-81. PubMed ID: 10769699
[TBL] [Abstract][Full Text] [Related]
3. Early modification of c-myc, Ha-ras and p53 expressions by chemical carcinogens (DMBA, MNU).
Budán F; Varjas T; Nowrasteh G; Prantner I; Varga Z; Ember A; Cseh J; Gombos K; Pázsit E; Gobel G; Bauer M; Gracza T; Arany I; Perjési P; Ember I; Kiss I
In Vivo; 2009; 23(4):591-8. PubMed ID: 19567395
[TBL] [Abstract][Full Text] [Related]
4. Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[alpha]anthracene-induced onco/suppressor gene action in vivo II: A 48-hour experiment.
Perjési P; Gyöngyi Z; Bayer Z
Anticancer Res; 2000; 20(3A):1839-48. PubMed ID: 10928116
[TBL] [Abstract][Full Text] [Related]
5. Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells.
Ikejiri F; Honma Y; Okada T; Urano T; Suzumiya J
Int J Oncol; 2018 Jun; 52(6):2061-2068. PubMed ID: 29620253
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.
Maj E; Filip-Psurska B; Świtalska M; Kutner A; Wietrzyk J
Int J Mol Sci; 2015 Nov; 16(11):27191-207. PubMed ID: 26580599
[TBL] [Abstract][Full Text] [Related]
7. Deuterium depletion can decrease the expression of C-myc Ha-ras and p53 gene in carcinogen-treated mice.
Gyöngyi Z; Somlyai G
In Vivo; 2000; 14(3):437-9. PubMed ID: 10904878
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive action of Imatinib, a tyrosine kinase inhibitor in the regulation of angiogenesis and apoptosis in rat model of lung cancer.
Kumar K; Ghanghas P; Sanyal SN
Mol Cell Biochem; 2018 Oct; 447(1-2):47-61. PubMed ID: 29453608
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression.
Kadivar A; Ibrahim Noordin M; Aditya A; Kamalidehghan B; Davoudi ET; Sedghi R; Akbari Javar H
Int J Mol Med; 2018 Jul; 42(1):414-424. PubMed ID: 29620139
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
11. Modulation of p53 and c-myc in DMBA-induced mammary tumors by oral glutamine.
Todorova VK; Kaufmann Y; Luo S; Klimberg VS
Nutr Cancer; 2006; 54(2):263-73. PubMed ID: 16898871
[TBL] [Abstract][Full Text] [Related]
12. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
13. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
14. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
15. Effect of cisplatin treatment on early activation of oncogenes in vivo.
Németh A; Gyöngyi Z; Nádasi E; Ember A; Olasz L; Nyárády Z; Skapinyecz J; Ember I
In Vivo; 2002; 16(5):307-10. PubMed ID: 12494868
[TBL] [Abstract][Full Text] [Related]
16. Original Research: Featured Article: Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development.
Callahan R; Chestnut BA; Raafat A
Exp Biol Med (Maywood); 2017 Jan; 242(1):53-67. PubMed ID: 27550925
[TBL] [Abstract][Full Text] [Related]
17. Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.
Haas B; Weber-Lassalle K; Frötschl R; Eckstein N
Regul Toxicol Pharmacol; 2016 Jun; 77():25-34. PubMed ID: 26924275
[TBL] [Abstract][Full Text] [Related]
18. [Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice].
Li L; Li YQ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Apr; 19(4):229-32. PubMed ID: 17448279
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
[TBL] [Abstract][Full Text] [Related]
20. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
